Oric Pharmaceuticals (ORIC) Non-Current Deffered Revenue (2019 - 2020)
Oric Pharmaceuticals' (ORIC) quarterly Non-Current Deffered Revenue came in at $219000.0 in Q4 2020, down 71.37% YoY from $765000.0 in Q1 2020, and down 39.0% on a QoQ basis from $359000.0 in Q3 2020.
Oric Pharmaceuticals (ORIC) Non-Current Deffered Revenue (2019 - 2020) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 2 years of Non-Current Deffered Revenue data on file, last reported at $219000.0 in Q4 2020.
- Quarterly Non-Current Deffered Revenue fell 71.37% year-over-year to $219000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $219000.0 (down 71.37% YoY) and the FY2020 annual result came in at $219000.0, down 71.37% from the prior year.
- Non-Current Deffered Revenue eased to $219000.0 in Q4 2020, from $359000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $765000.0 in Q4 2019 to a low of $219000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 219,000.00 |
| Sep 30, 2020 | 359,000.00 |
| Jun 30, 2020 | 500,000.00 |
| Mar 31, 2020 | 635,000.00 |
| Dec 31, 2019 | 765,000.00 |